Company raised $30 million in gross proceeds from registered direct offering Company expanded commercial team and appointed leading biopharmaceutical executives. | May 11, 2023
Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022 One-year ROMAN follow-up data presented at 2022 American Society for Radiation.
16.05.2022 - Company plans to submit a New Drug Application (NDA) for avasopasem for the treatment of radiotherapy-induced severe oral mucositis (SOM) by end of 2022 Data from its Phase 3 ROMAN trial of avasopasem for SOM will be presented in an oral .